State of Tennessee Treasury Department lowered its holdings in shares of Diplomat Pharmacy Inc (NYSE:DPLO) by 9.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,650 shares of the company’s stock after selling 4,099 shares during the period. State of Tennessee Treasury Department owned approximately 0.05% of Diplomat Pharmacy worth $756,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Diplomat Pharmacy in the third quarter worth approximately $191,000. Piedmont Investment Advisors LLC bought a new position in shares of Diplomat Pharmacy in the third quarter worth approximately $216,000. Fox Run Management L.L.C. bought a new position in shares of Diplomat Pharmacy in the fourth quarter worth approximately $244,000. D.A. Davidson & CO. bought a new position in shares of Diplomat Pharmacy in the fourth quarter worth approximately $278,000. Finally, Invictus RG lifted its stake in shares of Diplomat Pharmacy by 24.4% in the third quarter. Invictus RG now owns 13,820 shares of the company’s stock worth $286,000 after buying an additional 2,707 shares in the last quarter. 64.62% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have recently issued reports on the stock. Deutsche Bank cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and boosted their price objective for the company from $22.00 to $29.00 in a report on Friday, February 2nd. Credit Suisse Group raised shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price objective for the company in a report on Thursday, January 25th. Mizuho set a $25.00 price objective on shares of Diplomat Pharmacy and gave the company a “hold” rating in a report on Wednesday, January 24th. Zacks Investment Research cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Wednesday, February 21st. Finally, Lake Street Capital assumed coverage on shares of Diplomat Pharmacy in a report on Friday, February 9th. They set a “buy” rating and a $35.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Diplomat Pharmacy presently has an average rating of “Hold” and a consensus target price of $25.38.
In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 2,150,000 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $20.65, for a total transaction of $44,397,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 30.20% of the stock is currently owned by corporate insiders.
Shares of Diplomat Pharmacy Inc (NYSE DPLO) opened at $22.41 on Friday. Diplomat Pharmacy Inc has a twelve month low of $14.00 and a twelve month high of $27.78. The company has a market cap of $1,676.19, a P/E ratio of 106.71 and a beta of 1.32. The company has a current ratio of 0.97, a quick ratio of 0.66 and a debt-to-equity ratio of 0.70.
Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Monday, February 26th. The company reported $0.18 EPS for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company earned $0.08 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. equities research analysts predict that Diplomat Pharmacy Inc will post 0.93 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/16/state-of-tennessee-treasury-department-reduces-position-in-diplomat-pharmacy-inc-dplo.html.
Diplomat Pharmacy Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.